JP2008526761A - 多環式ビス−アミドmmp阻害剤 - Google Patents
多環式ビス−アミドmmp阻害剤 Download PDFInfo
- Publication number
- JP2008526761A JP2008526761A JP2007549640A JP2007549640A JP2008526761A JP 2008526761 A JP2008526761 A JP 2008526761A JP 2007549640 A JP2007549640 A JP 2007549640A JP 2007549640 A JP2007549640 A JP 2007549640A JP 2008526761 A JP2008526761 A JP 2008526761A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- aryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC1(CC(*)CC1)*=* Chemical compound CC1(CC(*)CC1)*=* 0.000 description 10
- VZKDYGUAEIZLJN-UHFFFAOYSA-N Cc(cc(CNC(c1ncnc(C(O)=O)c1)=O)cc1)c1F Chemical compound Cc(cc(CNC(c1ncnc(C(O)=O)c1)=O)cc1)c1F VZKDYGUAEIZLJN-UHFFFAOYSA-N 0.000 description 2
- DBSKPUISKCOJMG-UHFFFAOYSA-N C=NC(O[n]1nnc2c1cccc2)=N Chemical compound C=NC(O[n]1nnc2c1cccc2)=N DBSKPUISKCOJMG-UHFFFAOYSA-N 0.000 description 1
- YJJAZCPCJZXXQI-UHFFFAOYSA-N C=[Br]c(cc1C2)ccc1NCN2C(OCc1ccccc1)=O Chemical compound C=[Br]c(cc1C2)ccc1NCN2C(OCc1ccccc1)=O YJJAZCPCJZXXQI-UHFFFAOYSA-N 0.000 description 1
- FTOVHMPYRDNVEY-UHFFFAOYSA-N C=[Br]c1cccc(CN)c1 Chemical compound C=[Br]c1cccc(CN)c1 FTOVHMPYRDNVEY-UHFFFAOYSA-N 0.000 description 1
- UWABMQNPAYLFOK-UHFFFAOYSA-N CC(C)(C)OC(NCc1cc(OCC(F)(F)F)ccc1)=O Chemical compound CC(C)(C)OC(NCc1cc(OCC(F)(F)F)ccc1)=O UWABMQNPAYLFOK-UHFFFAOYSA-N 0.000 description 1
- LEFPSVCTBIWRFN-UHFFFAOYSA-N CC(C)(C)OC(NCc1cc([Br]=C)ccc1)=O Chemical compound CC(C)(C)OC(NCc1cc([Br]=C)ccc1)=O LEFPSVCTBIWRFN-UHFFFAOYSA-N 0.000 description 1
- BJJQRDCBXONBHY-HNNXBMFYSA-N CC(C)(C)OC(c1c(C)c(CC[C@@H]2NC(c3ncnc(C(O)=O)c3)=O)c2cc1)=O Chemical compound CC(C)(C)OC(c1c(C)c(CC[C@@H]2NC(c3ncnc(C(O)=O)c3)=O)c2cc1)=O BJJQRDCBXONBHY-HNNXBMFYSA-N 0.000 description 1
- ALVBVZBAIQWFJB-MHZLTWQESA-N CC(C)(C)OC(c1ccc([C@H](CC2)NC(c3ncnc(C(NCc4cc(CN(CC5)C(C(C6=O)=O)=C6N(C)C)c5cc4)=O)c3)=O)c2c1C)=O Chemical compound CC(C)(C)OC(c1ccc([C@H](CC2)NC(c3ncnc(C(NCc4cc(CN(CC5)C(C(C6=O)=O)=C6N(C)C)c5cc4)=O)c3)=O)c2c1C)=O ALVBVZBAIQWFJB-MHZLTWQESA-N 0.000 description 1
- GQAUPTTUSSLXPS-UHFFFAOYSA-O CC(C)(C)[OH+]C(NCc1cc(CN)ccc1)=O Chemical compound CC(C)(C)[OH+]C(NCc1cc(CN)ccc1)=O GQAUPTTUSSLXPS-UHFFFAOYSA-O 0.000 description 1
- DGIDKSAXXIYJLR-ARJAWSKDSA-N CC(C/C=C\C)N Chemical compound CC(C/C=C\C)N DGIDKSAXXIYJLR-ARJAWSKDSA-N 0.000 description 1
- GFKYJWBRMJXIPJ-UHFFFAOYSA-N CC(N(CC1)Cc2c1ccc(CN)c2)=O Chemical compound CC(N(CC1)Cc2c1ccc(CN)c2)=O GFKYJWBRMJXIPJ-UHFFFAOYSA-N 0.000 description 1
- FUCLNWSNDLXHKJ-UHFFFAOYSA-N CC(OC(Cc1c2ccc(Br)c1)C2=O)=O Chemical compound CC(OC(Cc1c2ccc(Br)c1)C2=O)=O FUCLNWSNDLXHKJ-UHFFFAOYSA-N 0.000 description 1
- FUCLNWSNDLXHKJ-JTQLQIEISA-N CC(O[C@@H](Cc1c2ccc(Br)c1)C2=O)=O Chemical compound CC(O[C@@H](Cc1c2ccc(Br)c1)C2=O)=O FUCLNWSNDLXHKJ-JTQLQIEISA-N 0.000 description 1
- QZCUJIGVGDYLPW-UHFFFAOYSA-N CCOC(c1nnn[n]1-c1cc(CCC2NC(c3ncnc(C(NCc(cc4)cc(C)c4F)=O)c3)=O)c2cc1)=O Chemical compound CCOC(c1nnn[n]1-c1cc(CCC2NC(c3ncnc(C(NCc(cc4)cc(C)c4F)=O)c3)=O)c2cc1)=O QZCUJIGVGDYLPW-UHFFFAOYSA-N 0.000 description 1
- IHFCXBBSRKHLQX-UHFFFAOYSA-N CN(c1cc(CN)ccc1O1)C1=O Chemical compound CN(c1cc(CN)ccc1O1)C1=O IHFCXBBSRKHLQX-UHFFFAOYSA-N 0.000 description 1
- DDHFKLTYYXNKSH-KRWDZBQOSA-N COC(c1cc(C(OCCOC(c2cc(C(N[C@@H](CCc3c4)c3ccc4C#N)=O)ncn2)=O)=O)ncn1)=O Chemical compound COC(c1cc(C(OCCOC(c2cc(C(N[C@@H](CCc3c4)c3ccc4C#N)=O)ncn2)=O)=O)ncn1)=O DDHFKLTYYXNKSH-KRWDZBQOSA-N 0.000 description 1
- QKZSXGGSKKEUIC-ZDUSSCGKSA-N COC(c1ncnc(C(N[C@@H](CCc2c3)c2ccc3C#N)=O)c1)=O Chemical compound COC(c1ncnc(C(N[C@@H](CCc2c3)c2ccc3C#N)=O)c1)=O QKZSXGGSKKEUIC-ZDUSSCGKSA-N 0.000 description 1
- JTSIXXBPJFSMKS-IBGZPJMESA-N COc1cccc(CNC(c2cc(C(N[C@@H](CCc3c4)c3ccc4-c3nnn[nH]3)=O)ncn2)=O)c1 Chemical compound COc1cccc(CNC(c2cc(C(N[C@@H](CCc3c4)c3ccc4-c3nnn[nH]3)=O)ncn2)=O)c1 JTSIXXBPJFSMKS-IBGZPJMESA-N 0.000 description 1
- UKKAGYLBFNWLRN-DPOXTQSCSA-N Cc(c(CC[C@@H]1NC(c2cc(C(NCc3ccc(CCN(C4)C(C(C5=O)N(C)C)C5=O)c4c3)=O)ncn2)=O)c1cc1)c1C(O)=O Chemical compound Cc(c(CC[C@@H]1NC(c2cc(C(NCc3ccc(CCN(C4)C(C(C5=O)N(C)C)C5=O)c4c3)=O)ncn2)=O)c1cc1)c1C(O)=O UKKAGYLBFNWLRN-DPOXTQSCSA-N 0.000 description 1
- HFSPXFZVZZMGEC-IBGZPJMESA-N Cc(cc(CNC(c1cc(C(N[C@@H](CC2)c(cc3)c2cc3-[n]2nnnc2C(N)=O)=O)ncn1)=O)cc1)c1F Chemical compound Cc(cc(CNC(c1cc(C(N[C@@H](CC2)c(cc3)c2cc3-[n]2nnnc2C(N)=O)=O)ncn1)=O)cc1)c1F HFSPXFZVZZMGEC-IBGZPJMESA-N 0.000 description 1
- VUTGEYVBGYVWGR-UHFFFAOYSA-N Cc(cc(CNC(c1ncnc(C(NC(CCc2c3)c2ccc3-c2n[n](C)nn2)=O)c1)=O)cc1)c1F Chemical compound Cc(cc(CNC(c1ncnc(C(NC(CCc2c3)c2ccc3-c2n[n](C)nn2)=O)c1)=O)cc1)c1F VUTGEYVBGYVWGR-UHFFFAOYSA-N 0.000 description 1
- BOPZVCOEOUFQET-FQEVSTJZSA-N Cc(cc(CNC(c1ncnc(C(N[C@@H]2c3ccc(C(O)=O)c(C)c3CC2)=O)c1)=O)cc1)c1F Chemical compound Cc(cc(CNC(c1ncnc(C(N[C@@H]2c3ccc(C(O)=O)c(C)c3CC2)=O)c1)=O)cc1)c1F BOPZVCOEOUFQET-FQEVSTJZSA-N 0.000 description 1
- UVAZQVVANNGXSP-NRFANRHFSA-N Cc(cc(CNC(c1ncnc(C(N[C@@H]2c3ccc(C(OC)=O)c(C)c3CC2)=O)c1)=O)cc1)c1F Chemical compound Cc(cc(CNC(c1ncnc(C(N[C@@H]2c3ccc(C(OC)=O)c(C)c3CC2)=O)c1)=O)cc1)c1F UVAZQVVANNGXSP-NRFANRHFSA-N 0.000 description 1
- ZMXYNJXDULEQCK-UHFFFAOYSA-N Cc(cc1)cc(N)c1O Chemical compound Cc(cc1)cc(N)c1O ZMXYNJXDULEQCK-UHFFFAOYSA-N 0.000 description 1
- DTGPFNICWVLWSJ-UHFFFAOYSA-N Cc(cc1)cc(N2C)c1OC2=O Chemical compound Cc(cc1)cc(N2C)c1OC2=O DTGPFNICWVLWSJ-UHFFFAOYSA-N 0.000 description 1
- GBLBFWAKNXWFFS-UHFFFAOYSA-N Cc(cc1N2)ccc1OC2=O Chemical compound Cc(cc1N2)ccc1OC2=O GBLBFWAKNXWFFS-UHFFFAOYSA-N 0.000 description 1
- DJHGJYZYJBZLOY-NRFANRHFSA-N Cc1c(CC[C@@H]2NC(c3cc(C(NCc(ccc4c5)cc4c[n]5C(C(C4=O)=O)=C4N)=O)ncn3)=O)c2ccc1C(N1)=NOC1=O Chemical compound Cc1c(CC[C@@H]2NC(c3cc(C(NCc(ccc4c5)cc4c[n]5C(C(C4=O)=O)=C4N)=O)ncn3)=O)c2ccc1C(N1)=NOC1=O DJHGJYZYJBZLOY-NRFANRHFSA-N 0.000 description 1
- YBIXREXYVBYDHU-UHFFFAOYSA-N N#Cc1cc(C(C(N2)=O)NC2=O)ccc1 Chemical compound N#Cc1cc(C(C(N2)=O)NC2=O)ccc1 YBIXREXYVBYDHU-UHFFFAOYSA-N 0.000 description 1
- NDVUETYYXRFYKO-UHFFFAOYSA-N N#Cc1cc(NC(C2)=O)c2cc1 Chemical compound N#Cc1cc(NC(C2)=O)c2cc1 NDVUETYYXRFYKO-UHFFFAOYSA-N 0.000 description 1
- HGZJJKZPPMFIBU-UHFFFAOYSA-N N#Cc1cccc(C=O)c1 Chemical compound N#Cc1cccc(C=O)c1 HGZJJKZPPMFIBU-UHFFFAOYSA-N 0.000 description 1
- WMQVUXNNPVXVKF-FQEVSTJZSA-N NC(C(C1=O)=O)=C1[n]1cc(cc(CNC(c2ncnc(C(N[C@@H](CCc3c4)c3ccc4C(N3)=NOC3=O)=O)c2)=O)cc2)c2c1 Chemical compound NC(C(C1=O)=O)=C1[n]1cc(cc(CNC(c2ncnc(C(N[C@@H](CCc3c4)c3ccc4C(N3)=NOC3=O)=O)c2)=O)cc2)c2c1 WMQVUXNNPVXVKF-FQEVSTJZSA-N 0.000 description 1
- YZIMVSYYLNJRLQ-IENPIDJESA-N NC([C@H](C1)O)c(cc2)c1cc2Br Chemical compound NC([C@H](C1)O)c(cc2)c1cc2Br YZIMVSYYLNJRLQ-IENPIDJESA-N 0.000 description 1
- FMOOLGUUUXSMIV-UHFFFAOYSA-N NCc1cc(N(CC2)C(C(C3=O)=O)=C3N)c2cc1 Chemical compound NCc1cc(N(CC2)C(C(C3=O)=O)=C3N)c2cc1 FMOOLGUUUXSMIV-UHFFFAOYSA-N 0.000 description 1
- MEIZZCDBWUDKDW-UHFFFAOYSA-N NCc1cc(OCC(F)(F)F)ccc1 Chemical compound NCc1cc(OCC(F)(F)F)ccc1 MEIZZCDBWUDKDW-UHFFFAOYSA-N 0.000 description 1
- JARRYVQFBQVOBE-UHFFFAOYSA-N O=C(C1)Nc2c1ccc(Br)c2 Chemical compound O=C(C1)Nc2c1ccc(Br)c2 JARRYVQFBQVOBE-UHFFFAOYSA-N 0.000 description 1
- KSONICAHAPRCMV-UHFFFAOYSA-N O=C(CC1)c(cc2)c1cc2Br Chemical compound O=C(CC1)c(cc2)c1cc2Br KSONICAHAPRCMV-UHFFFAOYSA-N 0.000 description 1
- KJCBAZFLVYNPNR-UHFFFAOYSA-N O=C(N(Cc1cc(Br)ccc11)CC1=O)OCc1ccccc1 Chemical compound O=C(N(Cc1cc(Br)ccc11)CC1=O)OCc1ccccc1 KJCBAZFLVYNPNR-UHFFFAOYSA-N 0.000 description 1
- KDHNLJURZLDUJS-QMMMGPOBSA-N O[C@@H](Cc1c2ccc(Br)c1)C2=O Chemical compound O[C@@H](Cc1c2ccc(Br)c1)C2=O KDHNLJURZLDUJS-QMMMGPOBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64079504P | 2004-12-31 | 2004-12-31 | |
US70626705P | 2005-08-08 | 2005-08-08 | |
PCT/US2005/047421 WO2006083454A1 (en) | 2004-12-31 | 2005-12-31 | Multicyclic bis-amide mmp inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008526761A true JP2008526761A (ja) | 2008-07-24 |
JP2008526761A5 JP2008526761A5 (US07928230-20110419-C00107.png) | 2009-02-19 |
Family
ID=36283720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007549640A Abandoned JP2008526761A (ja) | 2004-12-31 | 2005-12-31 | 多環式ビス−アミドmmp阻害剤 |
Country Status (7)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021511331A (ja) * | 2018-01-19 | 2021-05-06 | サイトキネティックス, インコーポレイテッド | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
JP2021529185A (ja) * | 2018-06-26 | 2021-10-28 | サイトキネティックス, インコーポレイテッド | 心臓サルコメア阻害剤 |
WO2023080258A1 (ja) * | 2021-11-08 | 2023-05-11 | 旭化成株式会社 | カルボニル化合物、カルボニル化合物の製造方法、イソシアネート化合物の製造方法、及びイソシアネート組成物 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070155737A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
US20060293345A1 (en) * | 2005-05-20 | 2006-12-28 | Christoph Steeneck | Heterobicyclic metalloprotease inhibitors |
EP1981855A2 (en) * | 2005-12-30 | 2008-10-22 | Alantos Pharmaceuticals Holding, Inc. | Substituted bis-amide metalloprotease inhibitors |
CA2658362A1 (en) * | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
EP2077846B1 (en) * | 2006-11-02 | 2011-10-12 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
EP2102211A2 (en) * | 2006-11-20 | 2009-09-23 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
WO2008063669A1 (en) * | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic matrix metalloprotease inhibitors |
US20080221094A1 (en) * | 2007-03-07 | 2008-09-11 | Harald Bluhm | Metalloprotease inhibitors containing a squaramide moiety |
WO2008149191A1 (en) * | 2007-06-05 | 2008-12-11 | Pfizer Inc. | Hetero bicyclic carboxamide derivatives and their pharmaceutical use and compositions |
CA2747670A1 (en) | 2008-12-19 | 2010-07-15 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
EP3868377A1 (en) | 2009-11-13 | 2021-08-25 | Receptos Llc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
KR101781233B1 (ko) | 2009-11-13 | 2017-09-22 | 셀진 인터내셔널 Ii 에스에이알엘 | 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 |
DK2498609T3 (en) * | 2009-11-13 | 2018-06-18 | Celgene Int Ii Sarl | SELECTIVE HETEROCYCLIC SPHINGOSIN-1 PHOSPHATRECEPTOR MODULATORS |
WO2012046869A1 (ja) | 2010-10-08 | 2012-04-12 | 持田製薬株式会社 | 環状アミド誘導体 |
JP5420796B2 (ja) | 2011-04-27 | 2014-02-19 | 持田製薬株式会社 | 新規3−ヒドロキシイソチアゾール1−オキシド誘導体 |
JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
WO2012177896A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
JP2014527511A (ja) | 2011-06-24 | 2014-10-16 | アムジエン・インコーポレーテツド | Trpm8拮抗剤及び治療におけるそれらの使用 |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
JP6584956B2 (ja) | 2012-12-21 | 2019-10-02 | アステラス インスティテュート フォー リジェネレイティブ メディシン | 多能性幹細胞から血小板を生産するための方法およびその組成物 |
RU2757571C2 (ru) * | 2016-11-01 | 2021-10-18 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРИДАЗИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc |
WO2019100106A1 (en) * | 2017-11-24 | 2019-05-31 | The University Of Sydney | Antibacterial compounds and methods of use thereof |
BR112021003496A2 (pt) | 2018-08-31 | 2021-05-18 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para tratar doença cardíaca, para tratar uma doença ou afecção associada à cardiomiopatia hipertrófica, ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, ou afecção que está associada à pequena cavidade do ventículo esquerdo e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, ou afecção selecionada dentre distrofias musculares e doenças de armazenamento de glicogênio, para inibir o sarcômero cardíaco |
GB201908453D0 (en) * | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
JP2024508526A (ja) | 2021-03-04 | 2024-02-27 | サイトキネティックス, インコーポレイテッド | 心筋サルコメア阻害剤 |
IL310592A (en) | 2021-08-03 | 2024-04-01 | Cytokinetics Inc | The process of preparing apicamtan |
CN115778930B (zh) * | 2022-12-08 | 2024-02-27 | 陕西中医药大学 | 一种具有血管舒张活性的二硫缩醛类化合物在制备具有血管舒张活性药物方面的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03004920A (es) * | 2001-02-14 | 2003-09-05 | Warner Lambert Co | Pirimidinas inhibidoras de metaloproteinasas de matriz. |
DE10160357A1 (de) * | 2001-12-08 | 2003-06-18 | Aventis Pharma Gmbh | Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen |
BR0315055A (pt) * | 2002-11-02 | 2005-08-16 | Aventis Pharma Gmbh | Diamidas de ácido pirimidin-4,6-dicarboxìilco para a inibição seletiva de colagenases |
DE10300017A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Selektive MMP 13 Inhibitoren |
-
2005
- 2005-12-30 US US11/324,037 patent/US20060173183A1/en not_active Abandoned
- 2005-12-31 EP EP05855910A patent/EP1843820A1/en not_active Withdrawn
- 2005-12-31 AU AU2005326659A patent/AU2005326659A1/en not_active Abandoned
- 2005-12-31 CA CA002589328A patent/CA2589328A1/en not_active Abandoned
- 2005-12-31 WO PCT/US2005/047421 patent/WO2006083454A1/en active Application Filing
- 2005-12-31 MX MX2007007895A patent/MX2007007895A/es not_active Application Discontinuation
- 2005-12-31 JP JP2007549640A patent/JP2008526761A/ja not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021511331A (ja) * | 2018-01-19 | 2021-05-06 | サイトキネティックス, インコーポレイテッド | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
JP7401439B2 (ja) | 2018-01-19 | 2023-12-19 | サイトキネティックス, インコーポレイテッド | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
JP2021529185A (ja) * | 2018-06-26 | 2021-10-28 | サイトキネティックス, インコーポレイテッド | 心臓サルコメア阻害剤 |
JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス, インコーポレイテッド | 心臓サルコメア阻害剤 |
WO2023080258A1 (ja) * | 2021-11-08 | 2023-05-11 | 旭化成株式会社 | カルボニル化合物、カルボニル化合物の製造方法、イソシアネート化合物の製造方法、及びイソシアネート組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2589328A1 (en) | 2006-08-10 |
WO2006083454A1 (en) | 2006-08-10 |
US20060173183A1 (en) | 2006-08-03 |
AU2005326659A1 (en) | 2006-08-10 |
MX2007007895A (es) | 2008-01-18 |
EP1843820A1 (en) | 2007-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008526761A (ja) | 多環式ビス−アミドmmp阻害剤 | |
JP5391351B2 (ja) | ヘテロ二環式メタロプロテアーゼ阻害薬 | |
JP5730281B2 (ja) | ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤 | |
TWI295670B (en) | Vanilloid receptor ligands and their use in treatments | |
CN101595084B (zh) | 用于调整激酶级联的二芳基组合物和方法 | |
JP2009522295A (ja) | 置換ビス−アミドメタロプロテアーゼ阻害剤 | |
SG185652A1 (en) | 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace) | |
TW200307539A (en) | Cycloalkyl inhibitors of potassium channel function | |
ES2768823T3 (es) | Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa | |
JP6278416B2 (ja) | 置換4−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 | |
JP2017505322A (ja) | 化合物の組成物およびその使用 | |
CA3201443A1 (en) | Tetrahydroquinoline derivative and medicinal use thereof | |
JP6434528B2 (ja) | 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 | |
CN105008347A (zh) | 作为钾离子通道抑制剂的异喹啉类化合物 | |
WO2016011940A1 (zh) | 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用 | |
ES2562903T3 (es) | Nuevo compuesto que tiene actividad inhibidora de PARP | |
JP6943239B2 (ja) | Kcnq2〜5チャネル活性化剤 | |
JP2002220386A (ja) | ベンジルアミン誘導体、その製法およびその合成中間体 | |
WO2009142321A1 (ja) | ウレア構造を有する新規チオフェンジアミン誘導体 | |
NZ623858A (en) | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
UA81271C2 (en) | 2-pyridone derivatives as inhibitors of neutrophile elastase, process for the preparation thereof and pharmaceutical composition based thereon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081225 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081225 |
|
A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20100816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100816 |